ARTICLE | Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
February 20, 2025 9:49 PM UTC
Switch Therapeutics is designing siRNAs that remain inactive until turned on inside cells containing a specific biomarker, allowing the company to selectively target cell types of interest within a tissue, without relying on surface proteins. The company has raised a $52 million series A and hopes to be in the clinic in 2026.
Whereas standard siRNA therapies comprise two RNA strands, co-founder and CEO Dee Datta told BioCentury that Switch Therapeutics Inc.’s therapies incorporate a third “sensor” strand that enables conditional activation. ...